Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the impact on patient-reported outcomes (PROs). METHODS: Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbai, Ana-Maria, Mease, Philip J., Helliwell, Philip S., FitzGerald, Oliver, Fleishaker, Dona L., Mundayat, Rajiv, Young, Pamela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434913/
https://www.ncbi.nlm.nih.gov/pubmed/36045453
http://dx.doi.org/10.1186/s41927-022-00298-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434913/
https://www.ncbi.nlm.nih.gov/pubmed/36045453
http://dx.doi.org/10.1186/s41927-022-00298-4

Ejemplares similares